Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Eiseman Lab Hillman Cancer Center Research Pavilion, G.10.8
5117 Centre Avenue, Pittsburgh, PA 15213

Research in the Eiseman laboratory encompasses the preclinical studies of potential anti-cancer agents, both in vitro and in vivo, and provides laboratory support for phase I clinical trials. In vitro studies include cytotoxicity studies and studies designed to investigate the mechanism of action of the agent under investigation and the metabolism of the compound. In vivo studies are directed at determining the toxicity, pharmacokinetics, pharmacodynamics, and efficacy of the potential therapeutic agents in rodent models. A range-finding toxicology study determines the maximum tolerated dose on the schedule and route proposed for further development. Pharmacokinetic studies are performed following an intravenous dose of the agent at the MTD and at three lower doses to determine linearity of pharmacokinetics. Biliary cannulation studies may be done to determine elimination of the compound and its metabolites in bile. Key molecular targets may be examined as part of either pharmacokinetic studies or efficacy studies. Compounds currently under investigation include: geldanamycin derivatives, topotecan analogues, glyoxalase inhibitors, anthracyclines, retinoic acid related compounds, small molecules targeting tubulin and motor proteins, compounds targeting phosphatases (Cdc25), photodynamic therapies, and several compounds under investigation through a contract with the NCI.

Recently the Eiseman laboratory has begun to investigate the use of elastic scattering spectrometry to non-invasively measure concentrations of compounds with absorbance spectra in the long visible region (600-800 nm). We are also providing analytical support for a phase I study of fenretinide for the Ireland Cancer Center in Cleveland.

Julie Eiseman, PhD

Back to Top